Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

NCT06333899 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

High Grade Glioma
Diffuse Intrinsic Pontine Glioma
Anaplastic Astrocytoma
Infant Type Hemispheric Glioma
Glioblastoma
Glioblastoma Multiforme
WHO Grade III Glioma
WHO Grade IV Glioma
Diffuse Midline Glioma, H3K27-altered

Interventions

DRUG: Lorlatinib
DRUG: Lorlatinib with chemotherapy1
DRUG: Lorlatinib with chemotherapy 2
DRUG: Lorlatinib post Radiation

Sponsor

Nationwide Children's Hospital

Collaborators

Pfizer